AzTrials
AzTrials

Pediatric ObesityCardMetSObNCT05908877

Cardio-Metabolic Risk Evaluation in Overweight and Obese Children

An observational study of Pediatric Obesity and Metabolic Syndrome, run by Neoped - Centru de Pediatrie at 1 site in Romania.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound parameters in order to stratify cardio-metabolic risk in obese children. Read more about this study

Who is it for?
Ages 1 year to 18 yearsHealthy volunteers can take part
What is being tested?
History and Clinical evaluation, Biological evaluation of the metabolic syndrome and components and Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage
How many people
50 participants
Where
1 siteRomania
Study dates
10 Jul 2023to 10 Jul 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: The group or cohort of patients will be selected form the population that addresses the primary care clinic - pediatric center - Neoped.

Who may be able to join

  • clinical diagnosis of overweight or obesity
  • informed consent of caregivers

Who cannot join

  • lean/normal weight subjects
  • monogenic or syndromic obesity
  • endocrine obesity (e.g., hypothyroidism, Cushing's syndrome)
  • medication-induced obesity
  • associated chronic diseases (other than components of the metabolic syndrome)
  • lack of informed consent of caregivers

Trial locations and contacts

1 site in 1 country.

Teofana O Bizerea-Moga, MD PhD contact

+40729093725

bizerea.teofana@umft.ro

Cornel Musei contact

neoped.medica@gmail.com

Romania1 site
  • Neoped - Centru de Pediatrie

    Timișoara, Timiș County, 300425

    Teofana O Bizerea-Moga, MD PhD, +40729093725, bizerea.teofana@umft.ro

    Cornel Musei, neoped.medica@gmail.com

Other trials in Romania

About this study

Official title: Complex Assessment and Monitoring of Cardio-metabolic Risk in Overweight and Obese Children

Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound parameters in order to stratify cardio-metabolic risk in obese children. Also, the specialized literature is poor regarding longitudinal follow-up and the importance of diet for reducing metabolic and cardiovascular complications in these children.

This study is designed to assess the hypothesis that the sustained improvement of lifestyle with regard to nutrition and exercise can reverse cardiometabolic multimorbidities in obese children as assessed by clinical, biological and ultrasound evaluation.

Read the detailed description

The Metabolic Syndrome (MetS) is a group of metabolic conditions that increase the risk of cardiovascular events, insulin resistance and type 2 diabetes. Obesity is often the first stage in the subsequent development of MetS. Further, one or more changes may occur, such as: an increase in triglycerides, low-density lipoprotein cholesterol (LDL-C), insulin resistance and blood pressure, respectively a decrease in high-density lipoprotein cholesterol (HDL-C) and glucose tolerance.

The term "nonalcoholic fatty liver disease" (NAFLD) refers to a spectrum of conditions ranging from steatosis to nonalcoholic steatohepatitis (NASH) and fibrosis rather than a single entity. The main risk factors are obesity and the metabolic dysregulations that it causes. Obesity contributes to the development of NAFLD because it not only leads to metabolic imbalance but also increases oxidative stress and mitochondrial dysfunction.

An early indication of metabolic and cardiovascular subclinical disease, is represented by an increase of the carotid intima-media thickness (CIMT), of subcutaneous and visceral adipose tissue, as well as the fatty liver deposition. B-mode ultrasound allows measuring of all these parameters thereby contributing to the early detection of changes at these levels.

The ever-increasing incidence of pediatric obesity, enhanced by the recent coronavirus (COVID-19) pandemic, imposes the need for clinical, paraclinical-imaging, biological, nutritional and psychological evaluation and monitoring of this population.

The study aims to develop an algorithm for the complex assessment of cardio-metabolic risk in overweight and obese children on the one hand, as well as to reduce this risk by establishing a nutrition and physical activity plan simultaneously with a continuous monitoring of the results obtained following this plan, on the other side.

Being tested
History and Clinical evaluation, Biological evaluation of the metabolic syndrome and components, Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage, Nutritional assessment, Psychological evaluation of the impact of obesity/overweight
Keywords
Pediatric MetS, NAFLD, CIMT, Nutrition, Psychology
Medical subject headings
Pediatric Obesity, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • History and Clinical evaluationOther

    HISTORY and CLINICAL EVALUATION and recording of the following parameters:

    • Gestational Age
    • Birth Weight
    • Gender
    • Weaning habits
    • Anthropometric indices: actual age; actual weight; actual height; body mass index BMI (kg/m2) + percentile; waist circumference; age for height; weight for height; height for age; height standard deviation score (SDS)
    • Vital parameters: heart rate (beats/min); respiratory rate (breaths/min); blood pressure (mmHg)
    • Adipose tissue
    • Subcutaneous fat tissue distribution
    • Acanthosis Nigricans
    • Stretch marks (striae)
    • Tanner Puberty Stage
  • Biological evaluation of the metabolic syndrome and componentsDiagnostic test

    LABORATORY INVESTIGATIONS will include:

    • Lipid Profile: total cholesterol (mmol/L); LDL - cholesterol (mmol/L); HDL - cholesterol (mmol/L); triglycerides (mmol/L)
    • Glucose - Insulin Profile: HbA1c (%); serum glucose (mmol/L); insulinemia (µUI/mL); HOMA Index
    • Liver Function: alanine aminotransferase (ALT or TGP) (U/L); gamma glutamyl transferase (GGT) (U/L)
    • Cardio-Vascular Risk - Inflammation - Oxidative Stress: ultrasensitive C-reactive protein (ng/mL); leptin (ng/mL); adiponectin (ng/mL); serum selenium (μg/L); glutathione peroxidase (GPx) (U/L)
  • Ultrasound evaluation of subclinical atherosclerosis and visceral fat storageDiagnostic test

    ULTRASOUND EVALUATION by:

    • Carotid Intima-Media Thickness (cIMT) Measurement using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a high frequency linear array probe (5-13 MHz) and a semi-automated software (Auto IMT+), according to the Mannheim Consensus
    • Measurements of Visceral-to-Subcutaneous-Fat Ratio using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a 7.5 (12) MHz linear transducer for subcutaneous fat and a 3.5 MHz convex transducer for visceral fat measurement
    • Ultrasound Quantification of Hepatic Steatosis: assessed with B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) using 3.5 MHz convex transducer; increased liver echogenicity, blurring of vascular margins and increased acoustic attenuation are the parameters considered in the quantification of hepatic steatosis
  • Nutritional assessmentOther

    NUTRITION CONSULT Initial consult will include: food habits survey aiming at identifying the nutritional factors that led to an increased Body Mass Index (BMI) and recommendations At reevaluations the food diary of the patients will be evaluated and recommendations will be adapted accordingly.

    The final visit will include evaluation of the food diary looking to identify the factors that have or have not helped to normalize BMI in order to recommend a long-term healthy lifestyle.

  • Psychological evaluation of the impact of obesity/overweightBehavioural

    PSYCHOLOGICAL ASSESSMENT by:

    Evaluation of pediatric health-related quality of life will be assessed with Pediatric Quality of Life Inventory (PedsQL). The questionnaire has 23 items and undertakes the four types of functioning: physical, emotional, social, and educational. It can be filled in by children as well as parents. Higher scores indicate better health-related quality of life.

    Another questionnaire that will be used is the the Rosenberg Self-Esteem Scale. It is composed of 10 questions and measures positive and negative feelings about the self. The answer range is from strongly agree to strongly disagree. A higher score means higher self-esteem.

    Drawing in children is a communicative tool, many times more than reading or language. It can measure the image of the self and the image of the others and is representative of the unconscious.

    Questionnaires and drawing interpretation will be done at the initial presentation and at every control visit.

Study groups in NCT05908877
Study groupRoleWhat they receive
Overweight and Obese ChildrenChildren diagnosed as overweight or obese, defined by the Centers for Disease Control and Prevention (CDC) as a BMI between the 85th and 95th percentile, or above the 95th percentile for the same age and sex, respectively.
Receives: Other: History and Clinical evaluation; Diagnostic Test: Biological evaluation of the metabolic syndrome and components; Diagnostic Test: Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage; Other: Nutritional assessment; Behavioral: Psychological evaluation of the impact of obesity/overweight

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes from Baseline Body Mass Index in Overweight or Obese Children after Physical Activity and Diet Interventions

    Initial measurement of the body mass index (BMI) followed by three additional measurements at 3,6 and 12 months will be performed. These aim to assess the changes from baseline body mass index (BMI) in overweight or obese children, after physical activity and diet interventions.

    Overweight and obesity are defined using age-specific BMI reference guidelines from the 2000 Centers for Disease Control and Prevention Child Growth Charts. Thus, overweight assumes BMI values between the 85th and 95th percentiles, and obesity implies values above the 95th percentile.

    Measured: 0,3,6 and 12 months

  2. Changes from Baseline Systolic Blood Pressure in Overweight or Obese Children after Physical Activity and Diet Interventions

    Initial evaluation of systolic blood pressure followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline systolic blood pressure in overweight or obese children, after physical activity and diet interventions.

    Arterial hypertension is diagnosed as a blood pressure value (systolic, diastolic or both), measured in mmHg, over the 95th percentile for age.

    Measured: 0,3,6 and 12 months

  3. Changes from Baseline Diastolic Blood Pressure in Overweight or Obese Children after Physical Activity and Diet Interventions

    Initial evaluation of diastolic blood pressure followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline diastolic blood pressure in overweight or obese children after physical activity and diet interventions.

    Arterial hypertension is diagnosed as a blood pressure value (systolic, diastolic or both), measured in mmHg, over the 95th percentile for age.

    Measured: 0,3,6 and 12 months

  4. Evaluation of Changes in Health-Related Quality of Life in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions, using the Pediatric Quality of Life Inventory (PedsQL)

    The questionnaire has 23 items and undertakes the four types of functioning: physical, emotional, social, and educational. It can be filled in by children as well as parents. Higher scores indicate better health-related quality of life.

    PedsQL will be used at the child's first assessment and reapplied at each control visit.

    Items on the PedsQL Generic Core Scales are reverse scored and transformed to a 0-100 scale. Higher scores indicate better health related quality of life:

    0 ("Never") = 100

    1. ("Almost Never") = 75
    2. ("Sometimes") = 50
    3. ("Often") = 25
    4. ("Almost Always") = 0 Scale scores are computed as the sum of the items over the number of items answered (to account for missing data). If more than 50% of items or more are missing, the Scale Score should not be computed.

    Measured: 0,6 and 12 months

  5. Evaluation of Changes in Individual Self-Esteem in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions, using the Rosenberg self-esteem scale

    This scale is composed of 10 questions and measures positive and negative feelings about the self. The answer range is from strongly agree to strongly disagree.

    The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.

    Measured: 0,6 and 12 months

Secondary outcomes (8)
  1. Ultrasound Evaluation of Changes in Liver Echogenicity in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions

    Initial ultrasound evaluation of liver echogenicity followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess changes in liver echogenicity and the reduction in hepatic steatosis grade, if diagnosed at onset, in overweight or obese children after physical activity and diet interventions.

    Non-Alcoholic Fatty Liver Disease (NAFLD) can be diagnosed on ultrasound based on some suggestive parameters: diffuse hyperechoic structure ("bright liver"), deep beam attenuation, liver-to-kidney contrast, bright vessel walls.

    Non-Alcoholic Fatty Liver Disease (NAFLD) classification:

    • Grade 1 (mild): diffuse increase in liver echogenicity, with normal visualization of intrahepatic vessels and of the diaphragm.
    • Grade 2 (moderate): blurred visualization of intrahepatic vessels and of the diaphragm.
    • Grade 3 (severe): intrahepatic vessels, diaphragm and the posterior region of the liver cannot be visualized.

    Measured: 0,3,6 and 12 months

  2. Ultrasound Evaluation of Changes in Visceral-to-Subcutaneous-Fat Ratio in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions

    Initial ultrasound measurement of visceral and subcutaneous fat followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess changes in visceral-to-subcutaneous-fat ratio in overweight or obese children after physical activity and diet interventions.

    Subcutaneous fat thickness (ScFT) is defined as the measurement from the skin-fat interface to the anterior aspect of the linea alba.

    Visceral fat thickness (VFT) is defined as the thickness from the linea alba to the anterior wall of the aorta.

    Measured: 0,3,6 and 12 months

  3. Changes of Carotid Intima-Media Thickness (CIMT) in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions

    Initial ultrasound measurement of the carotid intima-media thickness (CIMT) followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess changes in carotid intima-media thickness in overweight or obese children after physical activity and diet interventions.

    At every visit four measurements of CIMT at far wall of the common carotid artery, approximately 1 cm proximal to the bulb, in the end-diastolic phase (2 for the left and 2 for the right CCA) will be obtained.

    Measured: 0,3,6 and 12 months

  4. Changes from Baseline Serum Glucose Levels in Overweight or Obese Children after Physical Activity and Diet Interventions

    Initial evaluation of glucose levels followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline serum glucose levels in overweight or obese children after physical activity and diet interventions.

    Impaired glucose metabolism is defined as serum insulin levels over 15 mU/L or fasting blood glucose levels higher than 6.11 mmol/L.

    Measured: 0,3,6 and 12 months

  5. Changes from Baseline Serum Lipid Levels in Overweight or Obese Children after Physical Activity and Diet Interventions

    Initial evaluation of serum lipid levels followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline serum lipid levels in overweight or obese children after physical activity and diet interventions.

    Dyslipidemia is defined if triglyceride or total cholesterol levels exceed the 95th percentile for age and sex or if or high-density lipoprotein (HDL) cholesterol levels are below the 5th percentile for age and sex.

    Measured: 0,3,6 and 12 months

  6. Changes from Baseline Liver Function Tests in Overweight or Obese Children after Physical Activity and Diet Interventions

    Liver function will be assessed by determining serum levels of alanine aminotransferase (ALT or TGP) (U/L) and gamma glutamyl transferase (GGT) (U/L) at the initial evaluation, and again at 3, 6 and 12 months. The aim is to assess the changes from baseline ALT and GGT levels in overweight or obese children after physical activity and diet interventions.

    Measured: 0,3,6 and 12 months

  7. Changes from Baseline Serum Insulin Levels in Overweight or Obese Children after Physical Activity and Diet Interventions

    Initial evaluation of serum insulin levels followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline serum insulin levels in overweight or obese children after physical activity and diet interventions.

    In this study, IR will be evaluated by using the homeostasis model assessment for IR index (HOMA - IR), calculated using the following equation: HOMA - IR = fasting insulin (uU/mL) x fasting plasma glucose (mmol/L)/22.5.

    IR is diagnosed in a patient if HOMA-IR exceeds the 95th percentile for age and sex.

    Measured: 0,3,6 and 12 months

  8. Changes from Baseline Inflammatory and Oxidative Stress Markers in Overweight or Obese Children after Physical Activity and Diet Interventions

    Initial evaluation of inflammation and oxidative stress status by determining the serum levels of ultrasensitive C-reactive protein (ng/mL), leptin (ng/mL), adiponectin (ng/mL), selenium (μg/L) and glutathione peroxidase (GPx) (U/L). These parameters will be reevaluated at 3,6 and 12 months to assess the changes from baseline levels in overweight or obese children after physical activity and diet interventions.

    Measured: 0,3,6 and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2023
  2. Study start10 Jul 2023 (estimated)
  3. Primary completion10 Dec 2023 (estimated)
  4. Study completion10 Jul 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05908877
Sponsor's protocol ID
01:Cardio_MetS_Ob
Acronym
CardMetSOb
Status last verified
Jun 2023
First submitted
4 Dec 2022
Last updated
18 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Pediatric Obesity and Metabolic Syndrome, run by Neoped - Centru de Pediatrie at 1 site in Romania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Teofana O Bizerea-Moga, MD PhD (+40729093725, bizerea.teofana@umft.ro), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes from Baseline Body Mass Index in Overweight or Obese Children after Physical Activity and Diet Interventions (time frame: 0,3,6 and 12 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in